1. THU0363 EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND NORMAL VERSUS ELEVATED C-REACTIVE PROTEIN (CRP) AT BASELINE: ANALYSES FROM THE SENSCIS TRIAL. (2nd June 2020) Authors: Riemekasten, G.; Carreira, P.; Saketkoo, L. A.; Aringer, M.; Chung, L.; Pope, J.; Miede, C.; Stowasser, S.; Gahlemann, M.; Alves, M.; Khanna, D. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗